1
|
Xiao H, Feng Y, Goundry WRF, Karlsson S. Organic Solvent Nanofiltration in Pharmaceutical Applications. Org Process Res Dev 2024; 28:891-923. [PMID: 38660379 PMCID: PMC11036530 DOI: 10.1021/acs.oprd.3c00470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 02/22/2024] [Accepted: 02/28/2024] [Indexed: 04/26/2024]
Abstract
Separation and purification in organic solvents are indispensable procedures in pharmaceutical manufacturing. However, they still heavily rely on the conventional separation technologies of distillation and chromatography, resulting in high energy and massive solvent consumption. As an alternative, organic solvent nanofiltration (OSN) offers the benefits of low energy consumption, low solid waste generation, and easy scale-up and incorporation into continuous processes. Thus, there is a growing interest in employing membrane technology in the pharmaceutical area to improve process sustainability and energy efficiency. This Review comprehensively summarizes the recent progress (especially the last 10 years) of organic solvent nanofiltration and its applications in the pharmaceutical industry, including the concentration and purification of active pharmaceutical ingredients, homogeneous catalyst recovery, solvent exchange and recovery, and OSN-assisted peptide/oligonucleotide synthesis. Furthermore, the challenges and future perspectives of membrane technology in pharmaceutical applications are discussed in detail.
Collapse
Affiliation(s)
- Hui Xiao
- Early
Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Yanyue Feng
- Early
Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - William R. F. Goundry
- Early
Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Macclesfield SK10 2NA, United Kingdom
| | - Staffan Karlsson
- Early
Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| |
Collapse
|
2
|
Magne A, Carretier E, Ubiera Ruiz L, Clair T, Le Hir M, Moulin P. Recovery of Homogeneous Platinoid Catalysts from Pharmaceutical Media: Review on the Existing Treatments and the Perspectives of Membrane Processes. MEMBRANES 2023; 13:738. [PMID: 37623799 PMCID: PMC10456598 DOI: 10.3390/membranes13080738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 08/14/2023] [Accepted: 08/16/2023] [Indexed: 08/26/2023]
Abstract
Catalyst recovery is a major challenge for reaching the objectives of green chemistry for industry. Indeed, catalysts enable quick and selective syntheses with high reaction yields. This is especially the case for homogeneous platinoid catalysts which are almost indispensable for cross-coupling reactions often used by the pharmaceutical industry. However, they are based on scarce, expensive, and toxic resources. In addition, they are quite sensitive and degrade over time at the end of the reaction. Once degraded, their regeneration is complex and hazardous to implement. Working on their recovery could lead to highly effective catalytic chemistries while limiting the environmental and economic impacts of their one-time uses. This review aims to describe and compare conventional processes for metal removal while discussing their advantages and drawbacks considering the objective of homogeneous catalyst recovery. Most of them lead to difficulty recycling active catalysts due to their ability to only treat metal ions or to chelate catalysts without the possibility to reverse the mechanism. However, membrane processes seem to offer some perspectives with limiting degradations. While membranes are not systematically the best option for recycling homogeneous catalysts, current development might help improve the separation between pharmaceutical active ingredients and catalysts and enable their recycling.
Collapse
Affiliation(s)
- Adrien Magne
- Aix Marseille Univ., CNRS, Centrale Marseille, M2P2 UMR 7340, Equipe Procédés Membranaires (EPM), Europole de l’Arbois, BP80, Pavillon Laennec, Hall C, 13545 Aix en Provence Cedex, France; (A.M.); (E.C.)
- Sanofi Chimie, Laboratoire Génie des Procédés 1, Process Engineering, Global Chemistry Manufacturing & Control (CMC), 45 Chemin de Mételine, 04200 Sisteron, France; (L.U.R.); (T.C.); (M.L.H.)
| | - Emilie Carretier
- Aix Marseille Univ., CNRS, Centrale Marseille, M2P2 UMR 7340, Equipe Procédés Membranaires (EPM), Europole de l’Arbois, BP80, Pavillon Laennec, Hall C, 13545 Aix en Provence Cedex, France; (A.M.); (E.C.)
| | - Lilivet Ubiera Ruiz
- Sanofi Chimie, Laboratoire Génie des Procédés 1, Process Engineering, Global Chemistry Manufacturing & Control (CMC), 45 Chemin de Mételine, 04200 Sisteron, France; (L.U.R.); (T.C.); (M.L.H.)
| | - Thomas Clair
- Sanofi Chimie, Laboratoire Génie des Procédés 1, Process Engineering, Global Chemistry Manufacturing & Control (CMC), 45 Chemin de Mételine, 04200 Sisteron, France; (L.U.R.); (T.C.); (M.L.H.)
| | - Morgane Le Hir
- Sanofi Chimie, Laboratoire Génie des Procédés 1, Process Engineering, Global Chemistry Manufacturing & Control (CMC), 45 Chemin de Mételine, 04200 Sisteron, France; (L.U.R.); (T.C.); (M.L.H.)
| | - Philippe Moulin
- Aix Marseille Univ., CNRS, Centrale Marseille, M2P2 UMR 7340, Equipe Procédés Membranaires (EPM), Europole de l’Arbois, BP80, Pavillon Laennec, Hall C, 13545 Aix en Provence Cedex, France; (A.M.); (E.C.)
| |
Collapse
|